Neurological and cognitive alterations induced by MDMA in humans

Montgomery and colleagues frame MDMA (3,4‑methylenedioxymethamphetamine, commonly ‘ecstasy’) as an empathogenic phenethylamine stimulant with widespread recreational use since the 1980s and continuing prevalence internationally. The introduction summarises its pharmacology—oral use with peak plasma concentrations around 1.5–3.0 hours and acute stimulation of serotonin, dopamine and norepinephrine via transporter action—and notes longstanding concerns that repeated use might damage the serotonin system and produce lasting neurocognitive consequences. The authors also note how demonstrations of serotonergic neurotoxicity in humans are complicated by polydrug use, genetic and environmental variability, and reliance on self‑report. The paper sets out to review the human literature on cognitive performance and neuroimaging evidence for structural and functional brain changes associated with recreational MDMA/ecstasy use. Rather than re‑reviewing cellular mechanisms of toxicity (covered elsewhere in the special issue), the review focuses on human neuroimaging modalities (MRI, fNIRS, EEG, SPECT, PET), acute laboratory administration studies, animal findings as context, and behavioural studies of long‑term users, with an emphasis on where findings converge or remain uncertain.

The extracted text presents this work as a narrative review of human studies across multiple modalities and domains rather than as a methods‑driven systematic review; specific search strategies, inclusion/exclusion criteria, databases searched, date ranges and formal risk‑of‑bias methods are not clearly reported in the provided extraction. Within the paper the investigators do report undertaking a meta‑analysis for molecular imaging studies of serotonin transporter (SERT) availability, but the extraction does not give details of the meta‑analytic protocol (for example, study selection, statistical model, or heterogeneity assessment). Across the reviewed literature, the authors draw on structural and functional MRI studies (including voxel‑based morphometry and task‑based fMRI), functional near‑infrared spectroscopy (fNIRS) studies targeting prefrontal haemodynamics, electroencephalography (EEG) and event‑related potentials, molecular imaging using SPECT and PET with serotonin‑selective radioligands, controlled acute MDMA administration trials in laboratory settings, animal behavioural studies, and observational studies of recreational ecstasy/polydrug users. Where available, the review reports on dose ranges used in laboratory studies (commonly 75–125 mg, and some studies using 1 mg/kg), measures of lifetime or recent use in field studies, and comparisons between current users, former users and non‑using controls. Because many primary studies included recreational polydrug samples, the authors sometimes discuss comparator groups such as pure ecstasy users, polyvalent ecstasy users (ecstasy plus amphetamines/cannabis) and non‑user controls, and they report when studies statistically controlled for other drug use (e.g. cannabis). The extraction does not present statistical analysis plans or meta‑analytic metrics beyond reporting regional SERT reductions in the molecular imaging synthesis.

Structural MRI studies using voxel‑based morphometry have reported reduced grey matter volume in ecstasy users in frontal (Brodmann area 45), temporal (BA 21) and occipital (BA 18) cortices, and reductions in cerebellum and pons in some samples. Functional MRI findings are heterogeneous: several task‑fMRI studies found no performance differences between user groups and controls but observed altered activation patterns, often interpreted as compensatory recruitment. Examples include greater activation in right parietal cortex or right frontal and parietal regions during executive tasks, reduced activation in hippocampus in some adolescent user samples, and greater activity in medial/superior frontal gyri, thalamus, caudate and putamen during recall tasks (effects sometimes attenuated after controlling for cannabis use). Several fMRI studies reported null effects on task activation or performance, while EEG studies have shown atypical event‑related potentials despite similar behavioural performance. Functional near‑infrared spectroscopy (fNIRS) studies (four published to date in the extracted text) have produced more consistent evidence of altered prefrontal haemodynamics in ecstasy users. Three studies reported increased oxygenated haemoglobin (O2Hb) in bilateral dorsolateral prefrontal cortex (DLPFC) or medial PFC during executive and verbal tasks, interpreted as greater resource recruitment to maintain performance; one study reported reduced O2Hb in DLPFC and suggested prolonged vasoconstriction as an alternative explanation. In fNIRS samples, behavioural performance was typically similar between users and controls, and haemodynamic change was sometimes associated with frequency, lifetime dose and recency of use. None of the fNIRS studies in the extraction assessed recovery after prolonged abstinence. Molecular imaging (SPECT/PET) studies were synthesised in a meta‑analysis reported by the authors. Across regions measured, SERT availability was reduced in current ecstasy/polydrug users in 11 of 14 brain regions examined, including neocortical areas (frontal, parietal, temporal, occipital, DLPFC) and limbic regions (anterior and posterior cingulate, hippocampus, amygdala, insula). Some longitudinal and cross‑sectional studies suggest partial recovery of SERT binding with abstinence: reductions observed in current users were not always present in former users, and some studies reported positive correlations between duration of abstinence and SERT distribution volume ratios. However, SERT recovery did not uniformly parallel recovery of cognitive measures in the samples cited—for example, verbal memory deficits persisted in one sample after about 2.5 years of abstinence despite partial SERT recovery. Controlled acute administration studies in the laboratory provide a mixed picture. An earlier comprehensive review found limited evidence of acute cognitive effects across executive, attention and sensory domains, with most attention tasks showing no MDMA‑related changes at doses of 75–125 mg. More recent laboratory studies identified selective acute impairments: 75 mg MDMA impaired immediate and delayed recall and spatial memory in one study, and impaired prospective memory and some aspects of divided attention and tracking in others; 1 mg/kg reduced encoding of emotional information in a study using emotional memory paradigms. Acute effects sometimes interacted with sleep deprivation. Observational studies of long‑term recreational users indicate the most consistent behavioural finding is impairment in declarative memory (immediate and delayed recall of words and prose). Level of MDMA use (monthly frequency, yearly amount, lifetime dose) frequently predicted greater impairments, although some studies reported deficits even in novice users. Prospective memory deficits have been reported with some evidence of dose‑dependence; however, polydrug use—particularly cannabis and cocaine—emerged as an important confounder in many studies. Executive functions show a mixed pattern: inhibitory control is often spared in group comparisons, whereas set‑switching and spatial working memory have shown deficits in pooled analyses and some individual studies, with higher use associated with poorer performance and some deficits persisting after abstinence. Updating tasks with high cognitive load (complex n‑back or letter updating) more reliably disclose MDMA‑related impairments, while simpler tasks (backwards digit span, easier n‑back) often do not. Semantic fluency deficits appear on more demanding written tasks but are less consistent on shorter oral tests. Overall, many neurocognitive differences are subtle, apparent under high cognitive demand, and influenced by co‑occurring substance use and other sample heterogeneity. The extracted text highlights several methodological and contextual factors that moderate findings: variable purity and adulteration of ecstasy in recreational settings, widespread polydrug use in samples, small and heterogeneous study samples, sex and genetic differences affecting pharmacokinetics, and environmental factors during use (ambient temperature, vigorous physical activity). These factors complicate dose‑response interpretation and attribution of effects specifically to MDMA.

The authors conclude that a substantial body of human research reports MDMA/ecstasy‑related changes in cognition, brain structure and brain function, but that the overall picture is complex and characterised by heterogeneity. Functional neuroimaging findings are inconsistent across studies in direction and regional localisation, and many samples are small and variable in their definitions of users and controls. By contrast, molecular imaging studies that use serotonin‑selective radioligands provide more consistent evidence of serotonergic neuroadaptation associated with repeated use, with SERT reductions observed across multiple cortical and limbic regions; some studies also indicate partial recovery of SERT availability with abstinence. Despite the molecular imaging signal, the clinical significance of these neurobiological changes remains uncertain. The authors emphasise limitations that constrain inference: confounding by polydrug use and variable drug purity, small sample sizes, cross‑sectional designs in many studies, and limited data on dose and long‑term recovery of cognitive function. Their synthesis suggests that repeated ecstasy use produces subtle short‑to‑medium‑term neurocognitive and neurophysiological changes that may be at least partially reversible, but they call for more rigorous research to clarify dose‑response relationships, the role of polysubstance use in exacerbating effects, and interactions with genetic and lifestyle factors—questions they note are especially important given the ongoing clinical development of MDMA as an adjunct to psychotherapy.